The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease
Open accessAbstract
Alzheimer's disease is a growing concern in the modern world. As the currently available medications are not very promising, there is an increased need for the fabrication of newer drugs. Curcumin is a plant derived compound which has potential activities beneficial for the treatment of Alzheimer's disease. Anti-amyloid activity and anti-oxidant activity of curcumin is highly beneficial for the treatment of Alzheimer's disease. The insolubility of curcumin in water restricts its use to a great extend, which can be overcome by the synthesis of curcumin nanoparticles. In our work, we have successfully synthesized water-soluble PLGA coated- curcumin nanoparticles and characterized it using different techniques. As drug targeting to diseases of cerebral origin are difficult due to the stringency of blood-brain barrier, we have coupled the nanoparticle with Tet-1 peptide, which has the affinity to neurons and possess retrograde transportation properties. Our results suggest that curcumin encapsulated-PLGA nanoparticles are able to destroy amyloid aggregates, exhibit anti-oxidative property and are non-cytotoxic. The encapsulation of the curcumin in PLGA does not destroy its inherent properties and so, the PLGA-curcumin nanoparticles can be used as a drug with multiple functions in treating Alzheimer's disease proving it to be a potential therapeutic tool against this dreaded disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Anand, P., Nair, H. B., Sung, B., Kunnumakkara, A. B., Yadav, V. R., Tekmal, R. R., & Aggarwal, B. B. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.003 · Cited by 574
RetractedBioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543 · cited 2×
“Three different Phase I clinical trials have proven that curcumin is safe at high doses (12 g/day) [19].”
BackgroundBiodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Curcumin as “Curecumin”: From kitchen to clinic
Goel, A., Kunnumakkara, A. B., & Aggarwal, B. B. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.016 · Cited by 2,214
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08370.2001 · Cited by 1,530
Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A., & Maitra, A. (2007) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-5-3 · Cited by 1,090
Shaikh, J., Ankola, D. D., Beniwal, V., Singh, D., & Kumar, M. N. V. R. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.02.019 · Cited by 956
Current advances in research and clinical applications of PLGA-based nanotechnology
Lü, J.-M., Wang, X., Marin-Muller, C., Wang, H., Lin, P. H., Yao, Q., & Chen, C. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.15 · Cited by 903
Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability
Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004) · Journal of Drug Targeting · doi:10.1080/10611860400015936 · Cited by 742
Hanson, L. R., & Frey, W. H. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s3-s5 · Cited by 697
Garcia‐Alloza, M., Borrelli, L. A., Rozkalne, A., Hyman, B. T., & Bacskai, B. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04613.x · Cited by 661
The effect of curcumin (turmeric) on Alzheimer’s disease: An overview
Mishra, S., & Palanivelu, K. (2008) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.40220 · Cited by 599
Tsai, Y.-M., Chien, C.-F., Lin, L.-C., & Tsai, T.-H. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.06.030 · Cited by 535
A Potential Role of the Curry Spice Curcumin in Alzheimers Disease
Ringman, J., Frautschy, S., Cole, G., Masterman, D., & Cummings, J. (2005) · Current Alzheimer Research · doi:10.2174/1567205053585882 · Cited by 518
Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
Frautschy, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00300-1 · Cited by 514
Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy.
Mukerjee, A., & Vishwanatha, J. K. (2009) · PubMed · Cited by 444
Targeting the brain with PEG–PLGA nanoparticles modified with phage-displayed peptides
Li, J., Feng, L., Fan, L., Zha, Y., Guo, L., Zhang, Q., Chen, J., Pang, Z., Wang, Y., Jiang, X., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.031 · Cited by 296
Gao, X., Tao, W., Lu, W., Zhang, Q., Zhang, Y., Jiang, X., & Fu, S. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.01.038 · Cited by 295
Fujisawa, S., Atsumi, T., Ishihara, M., & Kadoma, Y. (2004) · PubMed · Cited by 270
Dementia: A problem for our age
Abbott, A. (2011) · Nature · doi:10.1038/475s2a · Cited by 241
Tosi, G., Costantino, L., Rivasi, F., Ruozi, B., Leo, E., Vergoni, A. V., Tacchi, R., Bertolini, A., Vandelli, M. A., & Forni, F. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.022 · Cited by 234
Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide
Mourtas, S., Canovi, M., Zona, C., Aurilia, D., Niarakis, A., La Ferla, B., Salmona, M., Nicotra, F., Gobbi, M., & Antimisiaris, S. G. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.027 · Cited by 230
Park, S.-Y., Kim, H.-S., Cho, E.-K., Kwon, B.-Y., Phark, S., Hwang, K.-W., & Sul, D. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.05.030 · Cited by 209 · cited 3×
“the secondary changes that occur during the disease like oxidative stress [12,13], inflammatory stress [11,14] and cholesterol”
BackgroundMolecular Orbital Basis for Yellow Curry Spice Curcumin's Prevention of Alzheimer's Disease
Balasubramanian, K. (2006) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0603533 · Cited by 188
Recent developments in Alzheimer's disease therapeutics
Rafii, M. S., & Aisen, P. S. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-7 · Cited by 187
Yanagisawa, D., Shirai, N., Amatsubo, T., Taguchi, H., Hirao, K., Urushitani, M., Morikawa, S., Inubushi, T., Kato, M. G., Kato, F., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.142 · Cited by 165
Partial Correction of Cystic Fibrosis Defects with PLGA Nanoparticles Encapsulating Curcumin
Cartiera, M. S., Ferreira, E. C., Caputo, C. R., Egan, M. E., Caplan, M. J., & Saltzman, W. M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900138a · Cited by 157
Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution
Vergoni, A. V., Tosi, G., Tacchi, R., Vandelli, M. A., Bertolini, A., & Costantino, L. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.02.005 · Cited by 150
Taylor, M., Moore, S., Mourtas, S., Niarakis, A., Re, F., Zona, C., Ferla, B. L., Nicotra, F., Masserini, M., Antimisiaris, S. G., et al. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.06.015 · Cited by 149
CNS Targets for multi-functional drugs in the treatment of Alzheimer?s and Parkinson?s diseases
Youdim, M. B. H., & Buccafusco, J. J. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0214-z · Cited by 135
A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting
Liu, J. K., Teng, Q., Garrity‐Moses, M. E., Federici, T., Tănase, D., Imperiale, M. J., & Boulis, N. M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.01.022 · Cited by 134
Synthesis and Modification of Functional Poly(lactide) Copolymers: Toward Biofunctional Materials
Noga, D. E., Petrie, T. A., Kumar, A., Weck, M., García, A. J., & Collard, D. M. (2008) · Biomacromolecules · doi:10.1021/bm800292z · Cited by 112
Neuron‐specific delivery of nucleic acids mediated by Tet1‐modified poly(ethylenimine)
Park, I., Lasiene, J., Chou, S.-H. S., Horner, P. J., & Pun, S. H. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1062 · Cited by 111
A pyrazole curcumin derivative restores membrane homeostasis disrupted after brain trauma
Sharma, S., Ying, Z., & Gómez‐Pinilla, F. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.08.027 · Cited by 83
Curcumin Labeling of Neuronal Fibrillar Tau Inclusions in Human Brain Samples
Mohorko, N., Repovš, G., Popović, M., Kovács, G. G., & Bresjanac, M. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181d709eb · Cited by 60
Developing pharmacological therapies for Alzheimer disease
Iqbal, K., & Grundke, I. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7221-9 · Cited by 46
RECENT DEVELOPMENTS IN ALZHEIMER’S DISEASE
Cras, P. P. (2001) · Acta Clinica Belgica · doi:10.1179/acb.2001.040 · Cited by 33
Mondalek, F. G., Ponnurangam, S., Govind, J., Houchen, C. W., Anant, S., Pantazis, P., & Ramanujam, R. P. (2010) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-8-17 · Cited by 14
Cited by
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
Tiwari, S. K., Agarwal, S., Seth, B., Yadav, A., Nair, S., Bhatnagar, P., Karmakar, M., Kumari, M., Chauhan, L. K. S., Patel, D. K., et al. (2014) · ACS Nano · doi:10.1021/nn405077y · Cited by 558
“Flow cytometry was carried out to study the cellular uptake of FITC-tagged CurPLGA-NPs (FITC-Cur-PLGA-NPs) following an earlier published method.(83) In brief, hippocampus-derived NSC were treated with FITC-Cur-PLGA-NPs and empty PLGA-NPs for 6 h.”
MethodDrug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Biopolymer nano-particles and natural nano-carriers for nano-encapsulation of phenolic compounds
Faridi Esfanjani, A., & Jafari, S. M. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2016.06.053 · Cited by 544
Lee, W.-H., Loo, C.-Y., Bebawy, M., Luk, F., Mason, R., & Rohanizadeh, R. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311040002 · Cited by 537
Metadata
- Authors
- Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., & Kumar, D. S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-05
- Volume
- 7
- Issue
- 3
- Pages
- e32616
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2055928970
- Cited by
- 442
- References
- 42
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.